Single cell RNA-sequencing (scRNA-seq) has emerged as a powerful approach to dissect tumors and their ecosystems by determining the state of individual cells and inferring partial genetic information from expressed transcripts. For infiltrating T cells, this provides a comprehensive approach to define T cell states in human tumors. For malignant cells, scRNA-seq paves the way to characterizing cellular states and their associated genotypes at cellular resolution. The Molecular Immunology Core (Core 1) provides standardized and reproducible methods to profile and characterize immune cells and malignant cells by scRNA-seq in glioblastoma in both patients and mouse models. Core 1 also provides expert personnel, facilitates the sharing of knowledge within the program, and maintain the sophisticated equipment necessary to generate data for all Projects. The Molecular Immunology Core will be led Dr. Mario Suv and Dr. Kai Wucherpfennig who will contribute their expertise in single-cell technologies and immune cell isolation.

Public Health Relevance

The Molecular Immunology Core provides centralized single-cell RNA-sequencing expertise to characterize immune cells and malignant cells in glioblastoma. We will provide know-how to profile both clinical samples and mouse models with these techniques, serving all projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA236749-01A1
Application #
9937110
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2020-07-03
Project End
2025-06-30
Budget Start
2020-04-01
Budget End
2021-03-31
Support Year
1
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115